Treatment for Chronic Cystitis
First-line treatment for chronic cystitis includes nitrofurantoin (100 mg twice daily for 5 days), fosfomycin trometamol (3 g single dose), or trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days) if local resistance is <20%. 1
First-Line Treatment Options
Nitrofurantoin: 100 mg twice daily for 5 days
- Preferred due to minimal resistance and high efficacy against E. coli
- Recommended by multiple guidelines including the American Urological Association and American College of Physicians 1
Fosfomycin trometamol: 3 g single dose
Trimethoprim-sulfamethoxazole: 160/800 mg twice daily for 3 days
Alternative Treatment Options
Pivmecillinam: 400 mg three times daily for 3-5 days
β-Lactam agents: 3-7 day regimens
- Including amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil
- Use only when first-line agents cannot be used
- Generally have inferior efficacy and more adverse effects 2
Fluoroquinolones: 3-day regimens
Special Considerations for Chronic/Recurrent Cases
Intravesical therapy: Hyaluronic acid and chondroitin sulfate
- Shown to be effective in reducing recurrent episodes
- Research indicates 72.7% of patients treated with HA-CS remained event-free at follow-up compared to only 30.4% with antibiotic therapy alone 3
- Works by improving urothelium thickness and reducing bacterial load
For interstitial cystitis (a form of chronic cystitis):
- Oral treatments include pentosan polysulfate, tricyclic antidepressants, and antihistamines
- Intravesicular therapies include hydrodistention, dimethyl sulfoxide, and heparin 4
Treatment Duration and Follow-Up
- Clinical improvement should occur within 48-72 hours of starting appropriate treatment
- No routine post-treatment urinalysis or urine cultures needed if symptoms resolve
- If symptoms persist beyond 72 hours or recur within 2 weeks:
- Obtain urine culture with susceptibility testing
- Adjust therapy accordingly
- Consider a 7-day regimen using another agent 1
Important Cautions
Avoid amoxicillin or ampicillin for empirical treatment due to poor efficacy and high prevalence of antimicrobial resistance 2, 5
Consider ecological safety of antimicrobial therapy:
- WHO classifies nitrofurantoin and furazidine in the ACCESS group (minimal collateral effect)
- Fosfomycin and cephalosporins are in the WATCH group 5
Monitor local resistance patterns:
- TMP-SMX resistance now approaches 18-22% in some regions of the US
- Resistance to nitrofurantoin and fluoroquinolones has remained low at approximately 2% 6
For patients with truly recurrent cystitis that does not respond to standard antimicrobial therapy, consider referral to a urologist for further evaluation and specialized treatment options.